Logo

WTO

UTime Limited

WTO

UTime Limited • NASDAQ
$1.17 ▼ -4.10% (-0.05)
Market Cap $42166
52w High $440.00
52w Low $1.15
Dividend Yield 0%
P/E 0
Volume 195.13K
Outstanding Shares 36.04K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $138.405M ▲ $131.555M ▲ $-127.317M ▼ -91.989% ▼ $-3.846K ▼ $-122.784M ▼
Q4-2024 $88.23M ▲ $25.264M ▲ $-50.398M ▼ -57.121% ▼ $-1.667K ▼ $-18.55M ▼
Q2-2024 $83.926M ▲ $13.746M ▼ $-10.395M ▲ -12.386% ▲ $-379.8 ▲ $-11.487M ▲
Q4-2023 $69.869M ▲ $85.361M ▲ $-68.368M ▼ -97.852% ▼ $-2.245K ▼ $-64.593M ▼
Q2-2023 $63.847M $11.332M $-6.404M -10.031% $-347.8 $-7.508M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $109.213M ▲ $206.034M ▼ $343.888M ▲ $-132.663M ▼
Q2-2025 $105.345M ▲ $697.865M ▲ $318.28M ▲ $384.776M ▲
Q4-2024 $76.675M ▼ $649.947M ▲ $287.34M ▲ $367.798M ▲
Q2-2024 $79.952M ▲ $308.509M ▼ $279.458M ▲ $33.946M ▼
Q4-2023 $71.934M $313.139M $272.407M $44.089M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-127.317M ▼ $-8.342M ▲ $0 ▼ $37.136M ▼ $105.845M ▲ $-8.342M ▲
Q4-2024 $-50.398M ▼ $-363.093M ▼ $5.52M ▲ $352.58M ▲ $-1.643M ▼ $-364.064M ▼
Q2-2024 $-10.486M ▲ $-13.083M ▼ $0 ▲ $19.583M ▲ $4.013M ▲ $-13.083M ▼
Q4-2023 $-73.351M ▼ $-10.452M ▼ $-696K ▲ $11.341M ▲ $-1.274M ▼ $-10.988M ▼
Q2-2023 $-7.133M $-2.343M $-1.102M $3.477M $64.99M $-3.372M

Five-Year Company Overview

Income Statement

Income Statement UTime’s income statement shows a very small business that is still far from covering its costs. Revenue has stayed low and somewhat volatile over the last few years, without a clear growth trend. Gross profit is positive but very thin, meaning the company has little room to absorb overhead and development spending. Operating losses have been persistent and have widened sharply in the most recent year, suggesting either heavier spending on the health-tech pivot, restructuring, or one-off charges on top of an already fragile base. Net losses have followed the same pattern, and the huge swings in reported earnings per share mainly reflect the impact of repeated reverse stock splits rather than fundamental profit improvement.

Balance Sheet

Balance Sheet The balance sheet is small and has weakened over time. Total assets are limited, with cash being a key component, and there is a modest but meaningful level of debt. The most notable change is that shareholder equity has turned negative in the latest year, meaning liabilities now exceed assets. That is a clear signal of financial strain and leaves little cushion against further losses. Combined with the history of reverse splits and capital raises, the picture is of a company that has had to repeatedly recapitalize itself just to stay afloat, with very little tangible asset backing.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, showing that the core business is consuming cash rather than generating it. Free cash flow has also been negative in each year, although capital spending has been very low, which fits with an asset-light, outsourcing-heavy model but can also reflect limited capacity to invest. The particularly large cash outflow in the prior year underscores how dependent the company has been on external financing. While recent fund-raising provides some breathing room, ongoing cash burn and a small balance sheet mean the business likely remains sensitive to any delays in its strategic pivot paying off.

Competitive Edge

Competitive Edge UTime is trying to reposition itself from a low-end mobile device maker into a health-focused wearables player. Its main strengths come from experience in cost-efficient manufacturing, long-standing OEM/ODM relationships, and distribution channels in emerging markets. The move into medically oriented wearables, including a blood-pressure smartwatch with regulatory approval in China and a health-tracking smart ring, gives it a more differentiated story than generic budget electronics. However, the markets it is entering are intensely competitive, dominated by large consumer-tech and specialized health-tech firms with stronger brands, deeper R&D budgets, and richer ecosystems. A moat based mainly on low cost and niche geographies is thin and can erode quickly if larger players target the same segments.

Innovation and R&D

Innovation and R&D On the innovation side, UTime is aiming high: AI-driven health analytics, blood-pressure monitoring wearables with medical certification, a health-focused smart ring, and a potential digital eldercare platform. The strategic idea is to build an integrated health-monitoring ecosystem rather than just sell cheap devices. This direction aligns with global trends toward remote monitoring and preventive care. The weak spots are execution capacity and proof. Public information on the uniqueness and accuracy of its AI models is limited, and the company lacks the track record of established health-tech players. With constrained finances, sustaining meaningful R&D and validating these products clinically and commercially could be challenging, even though the conceptual roadmap is appealing.

Summary

Overall, UTime is a very small, loss-making company attempting a major strategic pivot into health-tech wearables from a weak financial base. The financial statements highlight persistent losses, a shrinking and now negative equity position, and reliance on external capital to fund operations. On the positive side, the company is not standing still: it has introduced medically oriented wearables, secured at least one regulatory certification in China, and is pursuing AI-driven health analytics and eldercare partnerships, all aimed at carving out a niche in emerging markets. The key tension is between ambition and resources. The strategy targets attractive, growing markets, but the company’s scale, balance sheet, and competitive backdrop introduce high execution risk and a wide range of potential outcomes.

NEWS

November 12, 2025 · 4:10 PM UTC

UTime Limited Announces 1-for-100 Reverse Stock Split

Read more

November 5, 2025 · 9:15 AM UTC

UTime Limited Actively Expands Global Smart Wearable Device Market

Read more

November 3, 2025 · 9:15 AM UTC

UTime Limited Explores Application of AI Technology in Health Data Analysis

Read more

October 30, 2025 · 9:15 AM UTC

UTime Limited Releases Smart Ring, Focusing on Sleep and Continuous Health Monitoring

Read more

October 28, 2025 · 9:45 AM UTC

UTime Limited Launches Smartwatch with Integrated Blood Pressure Monitoring

Read more